Molecular Imaging of DNA Damage Response by [18F]-Olaparib PET

Inclusion Criteria

• •1. Patients \>18y, with biopsy-proven HPV-negative HNSCC, or patients \>40y with HPV-positive HNSCC and high-risk features (i.e. \> 10 smoke packs/year AND ≥N2b)
• •2. Treatment with chemoradiotherapy using platinum-based chemotherapy is anticipated
• •3. Recent archival tumour tissue (\<8 weeks prior to inclusion) should be available with suffi-cient residual material for determination of tumour PARP1 levels
• •4. Presence of a tumour lesion ≥10 mm in diameter
• •5. ECOG performance status 0-2
• •6. Negative pregnancy test in women with childbearing potential
• •7. Life expectancy \>3 months
• •8. Signed written informed consent and able to comply with the protocol
• •9. For stage II only: re-biopsy should be deemed feasible by the investigators (assessed by head-and-neck surgeon)